Adma is a good buy now?

**ADMA Biologics appears to be a strong buy at this time**, and here's why:

1. **Positive Earnings Forecast**: Analysts at HC Wainwright anticipate that ADMA Biologics will earn $0.55 per share for the year 2024, up from their prior forecast of $0.49. This revision indicates a more optimistic outlook on the company's financial performance.

2. **Increased Price Target**: HC Wainwright has lifted its target price for ADMA Biologics from $18.00 to $26.00, which suggests a potential for the stock to appreciate in value.

3. **Consensus Rating and Price Target**: Despite the increased price target, the consensus rating remains a "Buy" with an average price target of $21.40. This indicates that analysts believe the stock has room to grow from its current price.

4. **Technical Indicators**: Technical analysis suggests a bullish trend for ADMA Biologics. The stock is trading above its 5-Day, 10-Day, and 20-Day moving averages, which is a sign of short-term upward momentum. Additionally, the stock is trading at a higher price than its resistance level, which could indicate a breakout potential.

5. **Recent Performance**: ADMA Biologics has outperformed the S&P 500 and has experienced a significant price increase, quadrupling since the beginning of the year. The company's stock price reached an all-time high, reflecting investor confidence.
6. **Earnings and Revenue Beat Expectations**: ADMA Biologics reported a substantial year-over-year revenue increase of 78%, reaching $107.2 million, and a net income surge of 1,300%. The company's earnings per share (EPS) also surpassed expectations, with a reported EPS of $0.15 for the quarter, compared to an estimate of $0.13.
7. **Strategic Developments**: The company has made significant strategic moves, such as appointing KPMG as its new independent registered public accounting firm, which could enhance investor confidence in the company's financial reporting and compliance efforts.

In conclusion, ADMA Biologics is currently favored by analysts, with a positive earnings forecast, increased price target, and a consensus rating of "Buy." The company's strong recent performance and strategic developments further support the case for a potential investment. However, investors should always consider their own risk tolerance and investment goals before making any investment decisions.